A Phase 1 interventional study of ALT-803 in Advanced Solid Tumors, sponsored by Altor BioScience. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-22.
Sponsored by Altor BioScience (part of ImmunityBio, Inc.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,050 studies in Melanoma with a site in United States — 244 open to participants now, 438 under way, 32 of them phase 3. Melanoma · United States.
Among the 2,050 studies in Melanoma with a site in United States, this one is the 1,053rd largest by enrollment of the 1,750 interventional ones that give a count, is one of 81 that started in 2014, is one of 648 in phase 1, and was the 933rd registered.
3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.
Browse Melanoma studies →244 of the 2,050 studies in Melanoma with a site in United States are open now. Recruiting first, the newest first:
Children's Oncology Group · Sites in United States
Ages up to 25
John Kirkwood · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 18+
H. Lee Moffitt Cancer Center and Research Institute · Sites in United States
Ages 18+ · Healthy volunteers
University of Colorado, Denver · Sites in United States
Ages 55+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,050 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 935 · Phase 2 907 · Phase 3 115 · Phase 4 11
First in 1991; this study’s year is marked. 81 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 40 across 2,652 interventional studies indexed under Melanoma.
Median enrollment 37 across the 1,750 interventional studies, 156 across the 212 observational. Of the 1,484 that completed or were terminated, 598 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
801 of 2,050 have an industry lead sponsor. The 10 most frequent:
This study is registered under Altor BioScience, one of the names counted as ImmunityBio, Inc.. Under that name alone:
Altor BioScience is the lead sponsor of 15 studies on the registry; none are open to participants now.
ImmunityBio, Inc. has 5 studies filed under Melanoma — fewer than ten, so there is no comparison to draw.
138 of the studies in Melanoma with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05608291Phase 3Regeneron PharmaceuticalsA Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery | 2027-01-15 |
| NCT05987332Phase 3IDEAYA BiosciencesIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | 2027-01-15 |
| NCT06246916Phase 3Regeneron PharmaceuticalsA Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | 2027-03-22 |
| NCT01223248Phase 3Memorial Sloan Kettering Cancer CenterRandomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy | 2027-10 |
| NCT06112314Phase 3Immunocore LtdIMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) | 2027-10-16 |
Add all 138 to your calendar (.ics) → With an account.
Among the 2,050 studies in Melanoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The proposed clinical trial is a phase I, open-label, multi-center, dose-escalation study of ALT-803 in patients with surgically incurable advanced solid tumors: melanoma, renal cell, non-small cell lung and squamous cell head and neck cancer
This trial will investigate the safety and immunogenicity, immunomodulatory properties, and clinical benefits of treatment with weekly doses of ALT-803 in patients with advanced solid tumors.
3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.
This study's enrollment of 26 is below the median of 40 across 2,652 interventional studies indexed under Melanoma.
Browse Melanoma studies →Altor BioScience is the lead sponsor of 15 studies on the registry; none are open to participants now.
First submitted before Altor BioScience became part of ImmunityBio, Inc..
Compared within Melanoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
ENTRY CRITERIA:
DISEASE CHARACTERISTICS:
PRIOR/CONCURRENT THERAPY:
PATIENT CHARACTERISTICS
Performance Status
Bone Marrow Function
Hepatic Function
Kidney Function
Pulmonary Function
Cardiac Function
Other
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: ALT-803
Biological: ALT-803
Biological: ALT-803
Biological: ALT-803
Biological: ALT-803
Biological: ALT-803
Biological: ALT-803
Biological: ALT-803
Biological: ALT-803
N-803 will be administered at the following doses intravenously: 0.3/0.5, 1.0, 3.0, 6.0 ug/kg N-803 will be administered at the following does subcutaneously: 6.0, 10.0, 15.0, 20.0 ug/kg N-803 will be administered intratumorally at a dose of 10.0 ug/kg, followed by N-803 administered subcutaneously at a dose of 15.0 ug/kg. Each treatment cycle consists of 4 weeks on therapy and 2 weeks off. Patients will receive weekly dose of ALT-803 for 4 weeks (Days 1, 8, 15, and 22) used for the identification of the OBD and MTD. After a 2-week rest period (Weeks 5 and 6) and recovery of any dose limiting toxicities to grade 0-1 of Cycle 1, a second 6-week cycle (4 weeks on treatment and 2 weeks off) can begin. After a rest period during Weeks 5 and 6 of Cycle 2, stable or benefitting patients assessed at week 8 +/- 1 may receive up to 2 additional 6-week cycles.
Dose Limiting Toxicity
The safety endpoint is the MTD of ALT-803, defined as the dose level below that at which ≥2 of 6 patients experience a DLT.
Time frame: 9 months
Number of Participants Who Developed Anti-drug Antibodies to ALT-803
Immunogenicity of ALT-803 assessed by ELISA
Time frame: 14 days post final dose, up to 135 days
To Evaluate the Effect of Escalating Doses of ALT-803: Pharmacokinetics (Half Life and Tmax)
Pharmacokinetics of ALT-803 assessed by ELISA
Time frame: 24 hours post dose
To Evaluate the Effect of Escalating Doses of ALT-803: Pharmacokinetics (Cmax)
Pharmacokinetics of ALT-803 assessed by ELISA
Time frame: 24 hours after first dose
To Evaluate the Effect of Escalating Doses of ALT-803: Pharmacokinetics (AUC 0-t, AUC0-24, AUC0-infinity)
Pharmacokinetics of ALT-803 assessed by ELISA
Time frame: 24 hours after first dose
To Evaluate the Effect of Escalating Doses of ALT-803: Interferon Gamma (IFN-γ)
The level of immune response to autochthonous viral and tumor antigens by interferon gamma (IFN-γ) ELISPOT
Time frame: Cycle 1 Week 1, pre-dose; Cycle 1 Week 1, 30 minutes post dose; Cycle 1 Week 1, 2 hours post dose; Cycle 1 Week 1, 4 hours post dose; Cycle 1 Week 1, 8 hours post dose; Cycle 1 Week 1, 24 hours post dose
Objective Response Rate
Number of patients with CR, PR, SD, and PD
Time frame: Up to 6 months
| Milestone | N-803 IV 0.3/0.5 ug/kg | N-803 IV 1.0 ug/kg | N-803 IV 3.0 ug/kg | N-803 IV 6.0 ug/kg | N-803 Subcutaneous 6.0 ug/kg | N-803 Subcutaneous 10.0 ug/kg | N-803 Subcutaneous 15.0 ug/kg | N-803 Subcutaneous 20.0 ug/kg | N-803 Intratumoral 10.0 ug/kg Followed by N-803 15.0 ug/kg Subcutaneous |
|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 3 | 3 | 3 | 3 | 3 | 4 | 3 | 2 |
| Completed | 2 | 1 | 1 | 0 | 1 | 0 | 0 | 2 | 0 |
| Not completed | 0 | 2 | 2 | 3 | 2 | 3 | 4 | 1 | 2 |
| Withdrew: Death | 0 | 2 | 1 | 1 | 1 | 1 | 3 | 1 | 2 |
| Withdrew: Progressive disease | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 2 | 1 | 0 | 1 | 0 | 0 |
The safety endpoint is the MTD of ALT-803, defined as the dose level below that at which ≥2 of 6 patients experience a DLT.
| Participants | N-803 IV 0.3/0.5 ug/kg | N-803 IV 1.0 ug/kg | N-803 IV 3.0 ug/kg | N-803 IV 6.0 ug/kg | N-803 Subcutaneous 6.0 ug/kg | N-803 Subcutaneous 10.0 ug/kg | N-803 Subcutaneous 15.0 ug/kg | N-803 Subcutaneous 20.0 ug/kg | N-803 Intratumoral 10.0 ug/kg Followed by N-803 15.0 ug/kg Subcutaneous |
|---|---|---|---|---|---|---|---|---|---|
| Dose Limiting Toxicity | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
Immunogenicity of ALT-803 assessed by ELISA
| Participants | N-803 IV 0.3/0.5 ug/kg | N-803 IV 1.0 ug/kg | N-803 IV 3.0 ug/kg | N-803 IV 6.0 ug/kg | N-803 Subcutaneous 6.0 ug/kg | N-803 Subcutaneous 10.0 ug/kg | N-803 Subcutaneous 15.0 ug/kg | N-803 Subcutaneous 20.0 ug/kg | N-803 Intratumoral 10.0 ug/kg Followed by N-803 15.0 ug/kg Subcutaneous |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Who Developed Anti-drug Antibodies to ALT-803 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Pharmacokinetics of ALT-803 assessed by ELISA
| hours | N-803 IV 0.3ug/kg | N-803 IV 1.0 ug/kg | N-803 IV 3.0 ug/kg | N-803 IV 6.0 ug/kg | N-803 Subcutaneous 6.0 ug/kg | N-803 Subcutaneous 10.0 ug/kg | N-803 Subcutaneous 15.0 ug/kg | N-803 Subcutaneous 20.0 ug/kg | N-803 Intratumoral 10.0 ug/kg Followed by N-803 15.0 ug/kg Subcutaneous | N-803 IV 0.5ug/kg |
|---|---|---|---|---|---|---|---|---|---|---|
| Half life | 2.23 (2.23 to 2.23) | 4.58 (1.36 to 7.79) | 2.53 (2.53 to 2.53) | 1.41 (0.751 to 2.06) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 2.73 (2.3 to 3.15) | NA (NA to NA) |
| Tmax | 0.583 (0.583 to 0.583) | 0.542 (0.517 to 0.567) | 0.667 (0.533 to 0.8) | 0.650 (0.55 to 0.75) | 6.06 (4.0 to 8.12) | 24.0 (23.9 to 24.0) | 16.1 (8.0 to 24.3) | 16.1 (8.12 to 24.0) | 0.508 (0.5 to 0.517) | 0.500 (0.500 to 0.500) |
Pharmacokinetics of ALT-803 assessed by ELISA
| ng/mL | N-803 IV 0.3 ug/kg | N-803 IV 1.0 ug/kg | N-803 IV 3.0 ug/kg | N-803 IV 6.0 ug/kg | N-803 Subcutaneous 6.0 ug/kg | N-803 Subcutaneous 10.0 ug/kg | N-803 Subcutaneous 15.0 ug/kg | N-803 Subcutaneous 20.0 ug/kg | N-803 Intratumoral 10.0 ug/kg Followed by N-803 15.0 ug/kg Subcutaneous | N-803 IV 0.5 ug/kg |
|---|---|---|---|---|---|---|---|---|---|---|
| To Evaluate the Effect of Escalating Doses of ALT-803: Pharmacokinetics (Cmax) | 91.2 (91.2 to 91.2) | 11.5 (10.2 to 12.8) | 49.8 (39.9 to 59.6) | 86.0 (79.0 to 93.0) | 0.276 (0.152 to 0.401) | 0.352 (0.290 to 0.413) | 0.685 (0.443 to 0.928) | 0.280 (0.252 to 0.307) | 72.6 (26.5 to 119) | 2.26 (2.26 to 2.26) |
Pharmacokinetics of ALT-803 assessed by ELISA
| hr*ng/mL | N-803 IV 0.3ug/kg | N-803 IV 1.0 ug/kg | N-803 IV 3.0 ug/kg | N-803 IV 6.0 ug/kg | N-803 Subcutaneous 6.0 ug/kg | N-803 Subcutaneous 10.0 ug/kg | N-803 Subcutaneous 15.0 ug/kg | N-803 Subcutaneous 20.0 ug/kg | N-803 Intratumoral 10.0 ug/kg Followed by N-803 15.0 ug/kg Subcutaneous | N-803 IV 0.5ug/kg |
|---|---|---|---|---|---|---|---|---|---|---|
| AUC 0-t | 236 (236 to 236) | 14.7 (10.5 to 18.8) | 105 (65.2 to 145) | 289 (186 to 392) | 4.66 (2.74 to 6.59) | 5.19 (4.86 to 5.51) | 10.9 (8.67 to 13.2) | 4.57 (3.73 to 5.41) | 323 (82.1 to 565) | NA (NA to NA) |
| AUC0-24 | 236 (236 to 236) | 14.7 (10.6 to 18.8) | 145 (145 to 145) | 290 (187 to 393) | 2.73 (2.73 to 2.73) | 4.86 (4.86 to 4.86) | 10.9 (8.56 to 13.2) | 4.56 (3.73 to 5.4) | 323 (82.1 to 564) | NA (NA to NA) |
| AUC0-infinity | 236 (236 to 236) | 15.0 (10.5 to 19.4) | 145 (145 to 145) | 290 (187 to 393) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 324 (82.4 to 565) | NA (NA to NA) |
The level of immune response to autochthonous viral and tumor antigens by interferon gamma (IFN-γ) ELISPOT
| pg/mL | N-803 IV 0.3/0.5 ug/kg | N-803 IV 1.0 ug/kg | N-803 IV 3.0 ug/kg | N-803 IV 6.0 ug/kg | N-803 Subcutaneous 6.0 ug/kg | N-803 Subcutaneous 10.0 ug/kg | N-803 Subcutaneous 15.0 ug/kg | N-803 Subcutaneous 20.0 ug/kg | N-803 Intratumoral 10.0 ug/kg Followed by N-803 15.0 ug/kg Subcutaneous |
|---|---|---|---|---|---|---|---|---|---|
| C1, W1 pre dose | 2.7 ± 0.5037 | 1.528 ± 2.1609 | 2.015 ± 2.8496 | 0 ± 0 | 0.326 ± 0.3833 | 2.741 ± 2.3792 | 2.659 ± 4.6059 | 4.445 ± 7.6987 | 5.955 ± 0.5356 |
| C1, W1 30min post dose | 0 ± 0 | 3.433 ± 4.8551 | 1.420 ± 2.0082 | 0 ± 0 | 0.163 ± 0.2829 | 0.692 ± 1.1994 | 2.659 ± 4.6059 | 1.394 ± 2.4152 | 2.397 ± 3.3896 |
| C1, W1 2 hr post dose | 21.827 ± 25.6506 | 22.585 ± 2.9941 | 30.605 ± 36.7908 | 10.198 ± 13.8527 | 0 ± 0 | 1.525 ± 1.3373 | 0 ± 0 | 1.463 ± 2.5342 | 43.863 ± 42.2211 |
| C1, W1 4 hr post dose | 64.947 ± 85.0197 | 47.160 ± 37.1485 | 57.660 ± 56.4978 | 23.295 ± 28.1061 | 1.146 ± 1.7892 | 1.771 ± 2.2307 | 0.607 ± 1.0506 | 1.325 ± 2.2943 | 78.729 ± 63.0940 |
| C1, W1 8 hr post dose | 10.022 ± 14.1731 | 11.158 ± 4.7186 | 15.3 ± 9.8995 | 7.597 ± 9.5858 | 0 ± 0 | 2.123 ± 1.1098 | 2.479 ± 4.2939 | 1.598 ± 2.7676 | 22.293 ± 11.2426 |
| C1, W1 24 hr post dose | 0 ± 0 | 0.728 ± 1.0292 | 0.73 ± 1.0324 | 0 ± 0 | 0.84 ± 0.7962 | 3.825 ± 0.5214 | 4.389 ± 7.6013 | 1.664 ± 2.8823 | 4.078 ± 5.7676 |
Number of patients with CR, PR, SD, and PD
| Participants | N-803 IV 0.3/0.5 ug/kg | N-803 IV 1.0 ug/kg | N-803 IV 3.0 ug/kg | N-803 IV 6.0 ug/kg | N-803 Subcutaneous 6.0 ug/kg | N-803 Subcutaneous 10.0 ug/kg | N-803 Subcutaneous 15.0 ug/kg | N-803 Subcutaneous 20.0 ug/kg | N-803 Intratumoral 10.0 ug/kg Followed by N-803 15.0 ug/kg Subcutaneous |
|---|---|---|---|---|---|---|---|---|---|
| Stable disease | 2 | 1 | 2 | 0 | 2 | 0 | 3 | 0 | 1 |
| Progressive disease | 0 | 2 | 1 | 3 | 0 | 3 | 1 | 2 | 1 |
Collected over Up to 385 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| N-803 IV 0.3/0.5 ug/kg | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| N-803 IV 1.0 ug/kg | 2/3 (66.7%) | 1/3 (33.3%) | 3/3 (100%) |
| N-803 IV 3.0 ug/kg | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| N-803 IV 6.0 ug/kg | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| N-803 Subcutaneous 6.0 ug/kg | 1/3 (33.3%) | 0/3 (0%) | 3/3 (100%) |
| N-803 Subcutaneous 10.0 ug/kg | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| N-803 Subcutaneous 15.0 ug/kg | 3/4 (75%) | 2/4 (50%) | 4/4 (100%) |
| N-803 Subcutaneous 20.0 ug/kg | 1/3 (33.3%) | 2/3 (66.7%) | 3/3 (100%) |
| N-803 Intratumoral 10.0 ug/kg Followed by N-803 15.0 ug/kg Subcutaneous | 2/2 (100%) | 0/2 (0%) | 2/2 (100%) |
| Event | N-803 IV 0.3/0.5 ug/kg | N-803 IV 1.0 ug/kg | N-803 IV 3.0 ug/kg | N-803 IV 6.0 ug/kg | N-803 Subcutaneous 6.0 ug/kg | N-803 Subcutaneous 10.0 ug/kg | N-803 Subcutaneous 15.0 ug/kg | N-803 Subcutaneous 20.0 ug/kg | N-803 Intratumoral 10.0 ug/kg Followed by N-803 15.0 ug/kg Subcutaneous |
|---|---|---|---|---|---|---|---|---|---|
| Disease progressionGeneral disorders | 0/2 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 1/3 | 0/2 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 0/2 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 1/3 | 0/2 |
| Metastases to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/2 | 1/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 0/3 | 0/2 |
| HeadacheNervous system disorders | 0/2 | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 0/4 | 0/3 | 0/2 |
| HaematuriaRenal and urinary disorders | 0/2 | 0/3 | 1/3 | 0/3 | 0/3 | 0/3 | 0/4 | 0/3 | 0/2 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/2 | 0/3 | 0/3 | 1/3 | 0/3 | 0/3 | 0/4 | 0/3 | 0/2 |
| AnaemiaBlood and lymphatic system disorders | 0/2 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 1/4 | 0/3 | 0/2 |
| Injection site reactionGeneral disorders | 0/2 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 1/4 | 0/3 | 0/2 |
| PyrexiaGeneral disorders | 0/2 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 1/4 | 0/3 | 0/2 |
| Event | N-803 IV 0.3/0.5 ug/kg | N-803 IV 1.0 ug/kg | N-803 IV 3.0 ug/kg | N-803 IV 6.0 ug/kg | N-803 Subcutaneous 6.0 ug/kg | N-803 Subcutaneous 10.0 ug/kg | N-803 Subcutaneous 15.0 ug/kg | N-803 Subcutaneous 20.0 ug/kg | N-803 Intratumoral 10.0 ug/kg Followed by N-803 15.0 ug/kg Subcutaneous |
|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 2/2 | 1/3 | 1/3 | 1/3 | 0/3 | 1/3 | 0/4 | 1/3 | 0/2 |
| ChillsGeneral disorders | 1/2 | 2/3 | 0/3 | 1/3 | 0/3 | 0/3 | 1/4 | 1/3 | 2/2 |
| FatigueGeneral disorders | 2/2 | 1/3 | 2/3 | 1/3 | 0/3 | 3/3 | 3/4 | 1/3 | 2/2 |
| Injection site reactionGeneral disorders | 0/2 | 0/3 | 0/3 | 0/3 | 1/3 | 2/3 | 4/4 | 3/3 | 2/2 |
| PyrexiaGeneral disorders | 1/2 | 0/3 | 1/3 | 1/3 | 1/3 | 2/3 | 1/4 | 1/3 | 2/2 |
| Lymphocyte count decreasedInvestigations | 1/2 | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 2/4 | 1/3 | 2/2 |
| Decreased appetiteMetabolism and nutrition disorders | 0/2 | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 1/4 | 1/3 | 2/2 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 0/2 | 0/3 | 0/3 | 0/3 | 1/3 | 1/3 | 1/4 | 3/3 | 1/2 |
| HyponatraemiaMetabolism and nutrition disorders | 0/2 | 0/3 | 0/3 | 1/3 | 0/3 | 0/3 | 2/4 | 0/3 | 2/2 |
| PruritusSkin and subcutaneous tissue disorders | 2/2 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 0/3 | 0/2 |
| Age, Continuous(years) | N-803 IV 0.3/0.5 ug/kg | N-803 IV 1.0 ug/kg | N-803 IV 3.0 ug/kg | N-803 IV 6.0 ug/kg | N-803 Subcutaneous 6.0 ug/kg | N-803 Subcutaneous 10.0 ug/kg | N-803 Subcutaneous 15.0 ug/kg | N-803 Subcutaneous 20.0 ug/kg | N-803 Intratumoral 10.0 ug/kg Followed by N-803 15.0 ug/kg Subcutaneous | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 38.0 ± 15.56 | 64.7 ± 6.81 | 58.7 ± 10.26 | 69.7 ± 8.02 | 59.3 ± 5.13 | 59.0 ± 3.46 | 63.3 ± 9.88 | 55.3 ± 10.97 | 64.0 ± 19.8 | 59.9 ± 11.2 |
| Sex: Female, Male(Participants) | N-803 IV 0.3/0.5 ug/kg | N-803 IV 1.0 ug/kg | N-803 IV 3.0 ug/kg | N-803 IV 6.0 ug/kg | N-803 Subcutaneous 6.0 ug/kg | N-803 Subcutaneous 10.0 ug/kg | N-803 Subcutaneous 15.0 ug/kg | N-803 Subcutaneous 20.0 ug/kg | N-803 Intratumoral 10.0 ug/kg Followed by N-803 15.0 ug/kg Subcutaneous | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 0 | 2 | 1 | 1 | 1 | 3 | 1 | 0 | 11 |
| Male | 0 | 3 | 1 | 2 | 2 | 2 | 1 | 2 | 2 | 15 |
| Ethnicity (NIH/OMB)(Participants) | N-803 IV 0.3/0.5 ug/kg | N-803 IV 1.0 ug/kg | N-803 IV 3.0 ug/kg | N-803 IV 6.0 ug/kg | N-803 Subcutaneous 6.0 ug/kg | N-803 Subcutaneous 10.0 ug/kg | N-803 Subcutaneous 15.0 ug/kg | N-803 Subcutaneous 20.0 ug/kg | N-803 Intratumoral 10.0 ug/kg Followed by N-803 15.0 ug/kg Subcutaneous | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 2 |
| Not Hispanic or Latino | 2 | 3 | 3 | 2 | 3 | 2 | 4 | 3 | 2 | 24 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | N-803 IV 0.3/0.5 ug/kg | N-803 IV 1.0 ug/kg | N-803 IV 3.0 ug/kg | N-803 IV 6.0 ug/kg | N-803 Subcutaneous 6.0 ug/kg | N-803 Subcutaneous 10.0 ug/kg | N-803 Subcutaneous 15.0 ug/kg | N-803 Subcutaneous 20.0 ug/kg | N-803 Intratumoral 10.0 ug/kg Followed by N-803 15.0 ug/kg Subcutaneous | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 2 | 2 | 3 | 3 | 3 | 2 | 3 | 3 | 2 | 23 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 2 |
| Advanced Solid Tumors(Participants) | N-803 IV 0.3/0.5 ug/kg | N-803 IV 1.0 ug/kg | N-803 IV 3.0 ug/kg | N-803 IV 6.0 ug/kg | N-803 Subcutaneous 6.0 ug/kg | N-803 Subcutaneous 10.0 ug/kg | N-803 Subcutaneous 15.0 ug/kg | N-803 Subcutaneous 20.0 ug/kg | N-803 Intratumoral 10.0 ug/kg Followed by N-803 15.0 ug/kg Subcutaneous | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Count of participants | 2 | 3 | 3 | 3 | 3 | 3 | 4 | 3 | 2 | 26 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from May 2014 to primary completion in Aug 2017, 39 months.
Results were first posted in Jan 2025, 7 years 5 months after primary completion.
Of 226 industry-sponsored phase 1 interventional studies under Melanoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 66. This study's 39 months is below that.
Counting every sponsor, half of 412 studies reached it within 49 months; a quarter within 31 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nogapendekin alfa inbakicept